FDA Chief Marty Makary stated that an anticipated autism report has not yet been written, describing a Wall Street Journal story on the matter as premature. He indicated the report would be released within a month. Meanwhile, Kenvue's stock dropped following related news.

Makary's comments came in response to reports linking medications like Tylenol to autism discussions. The statement aims to clarify the timeline for the official report.

Context

• Report expected soon.
• Stock impact on Tylenol's parent company.

Reported in KFF Health News.